Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Medtronic’s ‘artificial pancreas’ for diabetes

Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.

Read More »

Forxiga combo beats use of drug alone

AstraZeneca said combining its Forxiga diabetes drug with Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own.

Read More »

Novo plans larger study for semaglutide

Novo Nordisk’s experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, paving the way for a bigger study on the drug’s benefits.

Read More »

Sanofi, Verily in $500 million diabetes joint venture

French drugmaker Sanofi and Google owner Alphabet’s life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech sectors.

Read More »

Lexicon Rockets on Late-Stage Diabetes Drug Data

Shares of Lexicon Pharmaceuticals were up more than 18 percent after the company announced its Phase III Type 1 diabetes trial met its primary endpoint.

Read More »

Valeant is sued over Philidor ties, alleged racketeering

Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.

Read More »

Regular nut nibbling linked to low inflammation

Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.

Read More »

Can anything contain U.S. drug costs?

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.

Read More »

FDA Delays Sanofi’s Potential New Diabetes Drug

New timelines were announced for a U.S. FDA decision on Iglarlixi, the fixed-ratio combination of Adlyxin (lixisenatide) and Lantus, for treating type 2 diabetes.

Read More »

2016 Annual Report: Top 200 Medicines

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom